Dapagliflozin transforms into heart failure drug

MDedge Cardiocast

Innhold levert av MDedge. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av MDedge eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

5+ y ago 9:40

MP3•Episoder hjem

DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug

Proof that dapagliflozin significantly helped heart failure patients without diabetes recategorizes the drug as a major agent for treating heart failure.

New hypertension cases halved with community-wide salt substitution

Social marketing principles achieved near-universal salt replacement, village by village, in rural Peru.

Ticagrelor: Modest benefit, bigger bleed risk in diabetes plus stable CAD

Patients with prior PCI fared a bit better and may be a target population for long-term DAPT therapy.

In PAD, dropping statins ups death risk 43%

Statin adherence saves lives in peripheral arterial disease.

87 episoder

#Science #Medicine #Cardiology #Cardiologynews #Biology #Fitness #MDedge #Cardiologists